“
“Case Description-2 English Pointers were suspected of having consumed toxic doses of methotrexate, a dihydrofolate reductase inhibitor frequently used in human and veterinary chemotherapeutic protocols.

Clinical Findings Potentially toxic plasma concentrations of methotrexate were detected in both dogs.

Results of physical examination, a CBC, blood

gas analysis, and serum biochemical analysis FGFR inhibitor were predominantly unremarkable, although 1 dog had mild hyponatremia (1372 mmol/L; reference range, 140 to 153 mmol/L) and mild hypocalcemia (1.03 mmol of ionized calcium/L; reference range, 1.13 to 1.33 mmol of ionized calcium/L).

Treatment and Outcome Point-of-care determination of plasma methotrexate concentrations was not available; thus, palliative care was provided. Emesis was induced in both dogs by SC administration of apomorphine, and 3 doses of selleck a suspension of activated charcoal with sorbitol were administered orally over a 6-hour period. Fluid diuresis was initiated in both dogs by administration of a compound sodium lactate solution, and N-acetylcysteine was administered IV to both dogs as a hepatoprotectant.

A solution of calcium folinate (also known as leucovorin) was administered IV to both dogs to mitigate the effects of ingested methotrexate. No adverse effects associated with calcium folinate administration were identified, and no clinical or pathological evidence of methotrexate intoxication was detected.

Clinical Relevance IV administration of calcium folinate appeared to prevent the pathological sequelae

of methotrexate intoxication without adverse effects. Administration of calcium folinate is recommended for the treatment of dogs with suspected or confirmed methotrexate overdose. Am Vet Med Assoc selleck products 2010;237:1450-1454)”
“The aim of this study was to optimize the preparation process of baicalin-beta-cyclodextrin inclusion compound (baicalin-beta-CD) by adopting Response Surface Methodology (RSM). On the basis of the single-factor experiment, the conditions of the inclusion process were optimized by adopting RSM with the factors to be investigated (i.e. the proportion of beta-CD and baicalin, inclusion time and inclusion temperature); the quadratic regression equation model of the inclusion rate of baicalin-beta-CD was constructed via simulation. The analysis of the experimental results showed that the optimal inclusion conditions are: proportion of beta-CD and baicalin of 2.51, inclusion time of 1.57 h, and inclusion temperature of 63.79 degrees C. There was a good compliance between the measured result of the inclusion rate (89.83%) and the predictive value (90.22%) of the equation obtained by fitting response surface.